Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease

PurposeTo identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease.MethodsThis study included 23 patients (46 eyes) with acute-phase VKHdivided into two subgroups: Group 1; acute-resolved (10 patients), group 2; chronic-recurrent (13 patients).ResultsMean age were 29.5 +/- 10.2 years in group 1, 35.8 +/- 12.2 years group 2 (p = .033). Best-corrected visual acuity with logMAR at admission was 0.91 +/- 0.65 in group 1, 0.88 +/- 0.62 in group 2 (p = .798), and improved to 0.08 +/- 0.24, 0.18 +/- 0.6, respectively (p = .557). Extraocular findings were detected in 30% in group 1, and 53.8% in group 2 at the time of admission (p = .108). All patients were treated with 1 g/day 3-5 days intravenous steroid, and 10 patients had immunomodulatory treatment. Initiation of immunomodulatory therapy did not affect the prognosis (p = .676).ConclusionOlder patients and/or who developed extraocular findings at the presentation were more prone to show recurrences.

Automated summary

The purpose of this study was to identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease. The study included 23 patients with acute-phase VKH, divided into two subgroups: acute-resolved (10 patients) and chronic-recurrent (13 patients). The results showed that older patients and/or those with extraocular findings at presentation were more likely to show recurrences. The initiation of immunomodulatory therapy did not affect the prognosis.